DexCom Reports Strong Second Quarter Performance with Growth and Strategic Expansions
DexCom reported a strong second quarter in fiscal year 2026, achieving 12% organic revenue growth driven by record new customer starts globally. The company secured coverage for over 7 million non-insulin type 2 diabetes patients across major U.S. pharmacy benefit managers and demonstrated significant clinical results from the CONNECT trial showing a 1.6% A1C improvement in this population. DexCom also expanded its product offerings by acquiring Nutrisense to integrate AI-based nutritional insights into its ecosystem, while launching Dexcom Flex in Germany and receiving Health Canada clearance for its G7 system. The company raised full-year organic growth guidance despite a projected $15 million foreign exchange headwind later this year. Operational improvements included 400 basis points of gross margin expansion to 64.1%, driven by manufacturing efficiencies, while the new Ireland facility is expected to temporarily impact margins before long-term benefits are realized.
Tickers: $DXCM
Topics: acquisition international_expansion product_launches regulatory_expansion revenue_growth